Recent euro strength may lead to a roughly 2% fall in European earnings, Citi says

Published 05/09/2025, 06:31 AM
© Reuters.

Investing.com - A rise in the euro versus the U.S. dollar so far this year could dent European corporate earnings by roughly 2%, analysts at Citi have estimated.

The euro has strengthened by around 10% against the greenback in 2025, fueled in part by many investors choosing to shift allocations away from the U.S. and into European assets. Heightened policy uncertainty and relatively better economic prospects in the rest of the world compared to the rest of the world have driven the trend, the analysts said.

They now anticipate that the euro will appreciate by around 5% from its current levels to $1.20 over the next six to twelve months.

European companies, many of which are heavily reliant on exports to support their businesses, could stand to be hit by the stronger euro, the Citi analysts led by Beata Manthey said in a note to clients.

The brokerage estimated that these foreign-exchange headwinds, coupled with ongoing uncertainty around the trajectory of U.S. President Donald Trump’s tariffs, could weigh on earnings from European firms -- particularly sectors like materials and energy.

However, the analysts noted that an appreciation in the euro has historically been offset by other factors, such as underlying economic conditions.

"Solid earnings per share growth remains possible when the euro is appreciating," they wrote. "Indeed, European forward earnings per share typically rises around 10% on average twelve months after a sizable euro rally, albeit with a wide range of outcomes."

Among some of the stock names Citi tips to benefit from a stronger euro are lenders like Commerzbank (ETR:CBKG) and PKO Bank (WA:PKO), as well as retailers like Zalando (ETR:ZALG) and Redcare Pharmacy (ETR:RDC). Companies that are boosted by a weaker euro, meanwhile, include materials firm UPM-Kymmene (HE:UPM), oil majors Shell (AS:SHEL) and BP (LON:BP), and drugmakers such as Novo Nordisk (CSE:NOVOb) and AstraZeneca (LON:AZN).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.